Multinational Asian Study on Watch-and-Wait Approach for Localized Rectal Adenocarcinoma After Neoadjuvant Therapy
Led by Tata Memorial Centre · Updated on 2024-11-20
337
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the safety and outcomes of the Watch-and-Wait approach in Asian patients with localized rectal adenocarcinoma who achieve a complete or near complete clinical response after neoadjuvant radiotherapy and chemotherapy. This observational study aims to build a multinational prospective database over five years, focusing on local regrowth rates as the primary outcome and assessing survival and quality of life among this population. The study addresses limited existing data on Asian patients and the impact of modern, more aggressive neoadjuvant therapies on this strategy.
The study collects data from several Asian institutes, enrolling patients treated with various neoadjuvant regimens including total neoadjuvant therapy and radiotherapy dose escalation. Participants are managed using the Watch-and-Wait strategy, which involves intense follow-up without immediate surgery to monitor tumor response and avoid or delay surgical intervention. The database will include detailed information on clinical responses, treatment regimens, and patient compliance.
Participants will undergo regular assessments including clinical evaluations, quality of life questionnaires EORTC QOL30 and QOL CR29, and monitoring for local regrowth and survival outcomes over a period of at least two years. Researchers will evaluate disease-free survival, colostomy-free survival, and patient adherence to follow-up protocols. This study aims to generate robust evidence to guide the safe adoption of Watch-and-Wait strategies in Asian patients with rectal cancer, with ongoing data collection expected until 2029.
CONDITIONS
Brief Title
Asian Watch-and-Wait Database (AWWD)
Research Team
D
Dr. Shivakumar Gudi, MBBS, MD (Radiation Oncology)
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Histologically confirmed diagnosis of adenocarcinoma of the rectum
Age 18 years or older
Clinical stage T1-T4, N0-N2, M0 at diagnosis
ECOG Performance status 0-1
Neoadjuvant treatment with either short course or long course radiation therapy and/or chemotherapy
Complete or near complete clinical response after neoadjuvant therapy
Patients willing to be on watch-and-wait strategy
Tumor located up to 10 cm from the anal verge (mid and low rectal tumors)
You will not qualify if you...
Recurrent rectal cancer
Any other concurrent medical or psychiatric condition or disease making the patient inappropriate for study entry
Not willing to consent for the study or to follow up routinely
Patients who cannot read or understand the language of quality of life questionnaires
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Monitoring
Duration - Up to 2 years
Participants who have achieved complete or near complete response after neoadjuvant therapy are closely monitored using an intense follow-up protocol to observe clinical outcomes without immediate surgery.
Frequent visits as per intense surveillance protocol over 2 years
Long-term Monitoring
Duration - Up to 5 years
Participants continue to be observed for long-term outcomes including survival and quality of life after the initial intensive monitoring period.
Periodic visits for follow-up assessments up to 5 years
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Study of Calderasib With Cetuximab and mFOLFOX6 Compared to mFOLFOX6 With or Without Bevacizumab for KRAS G12C-Mutant Advanced or Metastatic Colorectal Cancer
Phase III Trial Comparing Short-Course Versus Long-Course Radiotherapy Followed by Immunotherapy and Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer
Personalized Multimodal Treatment for Rectal Adenocarcinoma Focusing on Organ Preservation and Minimally Invasive Surgery
Phase 2 Study on Safety and Effectiveness of Short Course Radiation and CAPOX Chemotherapy Before Surgery for T2 Rectal Cancer
Phase II Multicenter Study Comparing Short-Course Radiotherapy Plus PD-1 Inhibitor and FOLFOX Chemotherapy with Long-Course Chemoradiotherapy in High-Risk Locally Advanced pMMRMSS Lower Rectal Adenocarcinoma
Phase I-II Study of PD1 AB122 and Adenosine Receptor AB928 Antagonists with Chemotherapy After Short-Course Radiation for Rectal Cancer
Phase II Study of Beta-Hydroxybutyrate Supplementation with Short-Course Radiotherapy, Immunotherapy, and CAPEOX Chemotherapy in Locally Advanced Rectal Cancer
Randomized Study Comparing Low Volume Transanal Irrigation by Qufora48 IrriSedo MiniGo with Conservative Treatment in Adults with Low Anterior Resection Syndrome
Phase 2 Study of Botensilimab and Balstilimab as Additional Treatment for Colorectal Cancer or Liver Metastases with Residual Tumor DNA After Surgery and Chemotherapy
Phase II Open-Label Study of Oral Fruquintinib with FOLFIRI for Adults with Metastatic Colorectal Cancer as Second-Line Treatment
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis.
Andrew G Renehan, Lee Malcomson, Richard Emsley...
Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial.
Renu R Bahadoer, Esmée A Dijkstra, Boudewijn van Etten...
Watch and wait after neoadjuvant treatment in rectal cancer: comparison of outcomes in patients with and without a complete response at first reassessment in the International Watch & Wait Database (IWWD).
Sofieke J D Temmink, Koen C M J Peeters, Renu R Bahadoer...
Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial.
Neoadjuvant chemoradiotherapy with radiation dose escalation with contact x-ray brachytherapy boost or external beam radiotherapy boost for organ preservation in early cT2-cT3 rectal adenocarcinoma (OPERA): a phase 3, randomised controlled trial.
Jean-Pierre Gerard, Nicolas Barbet, Renaud Schiappa...